0001209191-21-012547.txt : 20210219 0001209191-21-012547.hdr.sgml : 20210219 20210219191108 ACCESSION NUMBER: 0001209191-21-012547 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210217 FILED AS OF DATE: 20210219 DATE AS OF CHANGE: 20210219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: APPLE ROBERT F CENTRAL INDEX KEY: 0001054942 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32302 FILM NUMBER: 21657772 MAIL ADDRESS: STREET 1: C/O INKLINE PHARMACEUTICAL CO INC STREET 2: SENTRY PARK EAST 1720 WALTON ROAD CITY: BLUE BELL STATE: PA ZIP: 19422 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA, INC. CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 BUSINESS PHONE: 609-359-3020 MAIL ADDRESS: STREET 1: 100 PRINCETON SOUTH STREET 2: SUITE 300 CITY: EWING STATE: NJ ZIP: 08628 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20060120 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC DATE OF NAME CHANGE: 20020520 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-17 0 0001016169 ANTARES PHARMA, INC. ATRS 0001054942 APPLE ROBERT F C/O ANTARES PHARMA, INC. 100 PRINCETON SOUTH, SUITE 300 EWING NJ 08628 1 1 0 0 President & CEO Common Stock 2021-02-17 4 A 0 267878 0.00 A 2563033 D Common Stock 2021-02-17 4 F 0 116313 4.73 D 2446720 D Common Stock 2021-02-17 4 M 0 5519 2.62 A 2452239 D Common Stock 2021-02-17 4 S 0 5519 4.75 D 2446720 D Common Stock 2021-02-18 4 M 0 250000 0.88 A 2696720 D Common Stock 2021-02-18 4 S 0 232156 5.00 D 2464564 D Common Stock 2021-02-18 4 S 0 17844 5.01 D 2446720 D Common Stock 2021-02-18 4 S 0 241960 5.00 D 2204760 D Stock Option (right to buy) 2.62 2021-02-17 4 M 0 5519 0.00 D 2025-03-09 Common Stock 5519 0 D Stock Option (right to buy) 0.88 2021-02-18 4 M 0 250000 0.00 D 2026-03-09 Common Stock 250000 0 D On June 8, 2018, Mr. Apple was granted a performance stock unit award that was contingent upon achieving certain performance goals over the three-year performance period ended December 31, 2020. The number of shares acquired represent the total number of shares earned upon achievement of certain performance goals, which was certified and vested on February 17, 2021. The shares of common stock disposed represents the number of shares withheld by the company to settle tax liability in connection with the vesting of the performance stock unit award and were not actually sold. This stock option exercise and sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. This sale of common stock was effected pursuant to a Rule 10b5-1 trading plan. The options vested in equal quarterly installments over one year from the grant date of March 10, 2015. The options vested in equal quarterly installments over three years from the grant date of March 10, 2016. /s/Keith Muckenhirn as attorney-in-fact for Robert F. Apple 2021-02-19